Opiate Dependence
91
2
2
76
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Published Results
36 trials with published results (40%)
Research Maturity
76 completed trials (84% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.4%
4 terminated out of 91 trials
95.0%
+8.5% vs benchmark
26%
24 trials in Phase 3/4
47%
36 of 76 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 76 completed trials
Clinical Trials (91)
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Impact of Lofexidine on Stress, Craving and Opioid Use
Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder
Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
Substance Abuse Pre-Treatment Screening Study
Remote Observed Dosing of Suboxone to Improve Clinical Practice
Project Relief: Developing Brain Stimulation as a Treatment for Chronic Pain
CRAFT Behavior Therapy: Treatment Entry Component
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate Dependent
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia
A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone
Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment
Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone